A Pilot Phase II Study of Neoadjuvant Fulvestrant plus Abemaciclib in Women with Advanced Low-Grade Serous Carcinoma
Neoadjuvant chemotherapy shows limited activity in low-grade serous carcinoma of the ovary, fallopian tube, and peritoneum (LGSOC). Given the similarities between LGSOC and hormone receptor positive breast cancer, including clinical benefit from endocrine therapies, we conducted a phase II pilot study to assess the clinical benefit of neoadjuvant treatment with fulvestrant and abemaciclib for women with advanced LGSOC. Women with untreated, unresectable stage III or IV LGSOC were eligible. Patients received fulvestrant and abemaciclib treatment, Imaging re-assessment was performed every 8 weeks using RECIST 1.1 until deemed resectable. Following interval cytoreductive surgery (ICS), patients received 4 cycles of adjuvant fulvestrant and abemaciclib followed by maintenance letrozole. Pre- and post-treatment tumor samples were obtained for 15 patients in this cohort were obtianed for whole-exome sequencing.